grant
International Tuberculosis Clinical Research
Organization NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESLocation UNITED STATES
NIHUS FederalResearch GrantFY2025Active Follow-upAlaska IndianAlaska NativeAlaskan AmericanAlaskan IndianAlaskan NativeAlaskan Native AmericanAminoglycosidesAntitubercular AgentsAntitubercular DrugsApplied ResearchApplied ScienceAreaAwardBiological MarkersCOVID complicationsCOVID crisisCOVID epidemicCOVID pandemicCOVID related complicationsCOVID-19 complicationsCOVID-19 crisisCOVID-19 epidemicCOVID-19 eraCOVID-19 global health crisisCOVID-19 global pandemicCOVID-19 health crisisCOVID-19 pandemicCOVID-19 periodCOVID-19 public health crisisCOVID-19 related complicationsCOVID-19 yearsCXRCause of DeathCharacteristicsChinaChineseClassificationClinicalClinical ResearchClinical StudyClinical TrialsCollaborationsConduct Clinical TrialsCountryCross Sectional AnalysisCross-Sectional AnalysesCross-Sectional StudiesCross-Sectional SurveyDNA mutationDataData AnalysesData AnalysisDeveloping CountriesDeveloping NationsDiagnostic testsDiagnostics ResearchDiseaseDisease Frequency SurveysDisease OutbreaksDisorderDrug CombinationsDrug resistanceDrug resistance in MtbDrug resistance in Mycobacterium TuberculosisDrug resistant M TuberculosisDrug resistant MtbDrug resistant Mycobacteria TuberculosisDrugsEnrollmentEuropeanExtreme drug resistant tuberculosisExtremely drug resistant tuberculosisFailureFluoroquinolonesFoundationsFundingFutureGeneral RadiologyGenetic ChangeGenetic defectGenetic mutationGoalsHealth ResourcesINH resistanceINH resistantImmune MarkersImmunologic MarkersInfectious AgentInternationalInterventionInvestigatorsIsoniazid resistanceIsoniazid resistantJournalsKansasLactam AntibioticsLesionLess-Developed CountriesLess-Developed NationsLow-resource areaLow-resource communityLow-resource environmentLow-resource regionLow-resource settingM . tuberculosis resistanceM tbM tuberculosisM tuberculosis infectionM. tbM. tb infectionM. tuberculosisM. tuberculosis infectionM.tb infectionM.tuberculosis infectionMDR TuberculosisMDR-TBMTB infectionMagazineMainland ChinaManuscriptsMeasurementMedicalMedicationMedicineMeropenemMethodologyMethodsMicrobiologyMissouriMolecularMonobactam AntibioticsMonobactamsMonocyclic beta-LactamsMtb drug resistanceMtb resistanceMulti-Drug Resistant TuberculosisMultiDrug Resistance TuberculosisMultidrug-Resistant TuberculosisMutationMycobacterium tuberculosisMycobacterium tuberculosis (MTB) infectionMycobacterium tuberculosis infectionMycobacterium tuberculosis resistanceNIAIDNational Institute of Allergy and Infectious DiseaseNational Institutes of HealthNatural SciencesNew EnglandNortheastern United StatesOutbreaksPET/CTPET/CT scanParticipantPatientsPatternPharmaceutical PreparationsPhasePopulationProtocolProtocols documentationProvincePublic HealthPublishingRadiographyRadiologyRadiology SpecialtyRegimenRelapseReportingRepublic of KoreaResearchResearch PersonnelResearch ResourcesResearchersResidualResidual stateResource-constrained areaResource-constrained communityResource-constrained environmentResource-constrained regionResource-constrained settingResource-limited areaResource-limited communityResource-limited environmentResource-limited regionResource-limited settingResource-poor areaResource-poor communityResource-poor environmentResource-poor regionResource-poor settingResourcesRiskRoentgenographySARS-CoV-2 epidemicSARS-CoV-2 global health crisisSARS-CoV-2 global pandemicSARS-CoV-2 pandemicSARS-coronavirus-2 epidemicSARS-coronavirus-2 pandemicSamplingSampling StudiesScienceSevere Acute Respiratory Syndrome CoV 2 epidemicSevere Acute Respiratory Syndrome CoV 2 pandemicSevere acute respiratory syndrome coronavirus 2 epidemicSevere acute respiratory syndrome coronavirus 2 pandemicSouth AfricaSouth AfricanSouth CarolinaSouth KoreaSputumSystematicsTB chemotherapyTB diagnosisTB drugsTB infectionTB therapyTB treatmentTechnologyTestingThird-World CountriesThird-World NationsThoracic RadiographyTranslational ResearchTranslational ScienceTreatment PeriodTreatment ProtocolsTreatment RegimenTreatment ScheduleTuberculosisTuberculosis diagnosisTuberculostatic AgentsUnder-Developed CountriesUnder-Developed NationsUnited States National Institutes of HealthUniversitiesXDR-TBXDR-Tuberculosisactive followupanti-TBanti-TB drugsanti-tuberculosisanti-tuberculosis drugsantiTBarmbactericidalbactericidebio-markersbiologic markerbiomarkerchest X raychest Xraychest radiographyclinical candidateclinical developmentclinical diagnosticscomplications due to COVID-19coronavirus disease 2019 crisiscoronavirus disease 2019 epidemiccoronavirus disease 2019 global health crisiscoronavirus disease 2019 global pandemiccoronavirus disease 2019 health crisiscoronavirus disease 2019 pandemiccoronavirus disease 2019 public health crisiscoronavirus disease crisiscoronavirus disease epidemiccoronavirus disease pandemiccoronavirus disease-19 global pandemiccoronavirus disease-19 pandemiccytokinedata interpretationdeveloping countrydeveloping nationdiagnosed with TBdiagnosed with Tuberculosisdisease diagnosisdisease riskdisorder riskdisseminated TBdisseminated tuberculosisdrug adherencedrug candidatedrug compliancedrug detectiondrug resistance M Tuberculosisdrug resistance Mycobacteria Tuberculosisdrug resistantdrug resistant M.tbdrug testingdrug-sensitivedrug/agenteffective therapyeffective treatmentenrollextensively drug resistant TBextensively drug resistant tuberculosisfollow upfollow-upfollowed upfollowupgenome mutationimmune-based biomarkersimmunological biomarkersimmunological markersimprovedinfection due to Mycobacterium tuberculosisinfectious organismlung radiographymedical diagnosticmedication adherencemedication compliancemtbmultidrug-resistant TBnew diagnosticsnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation diagnosticsnext generation therapeuticsnovelnovel diagnosticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypositron emission computed tomographyprospectivepulmonaryradiographic chest imageradiographic lung imageradiological imagingrate of changeresistance in M . tuberculosisresistance in Mycobacterium tuberculosisresistance to Drugresistance to isoniazidresistant M . tuberculosisresistant Mtbresistant Mycobacterium tuberculosisresistant to Drugresistant to isoniazidresponse to therapyresponse to treatmentsecondary analysissevere acute respiratory syndrome coronavirus 2 global health crisissevere acute respiratory syndrome coronavirus 2 global pandemicstandard carestandard treatmentsuccesstherapeutic responsetherapy responsethoracic radiogramthorax radiographytranslation researchtranslational investigationtreat M. tuberculosistreat Mtbtreat Mycobacterium tuberculosistreat tbtreat tuberculosistreatment daystreatment durationtreatment responsetreatment responsivenesstreatment strategytuberculosis chemotherapytuberculosis drugstuberculosis infectiontuberculosis therapytuberculosis treatmenttuberculous spondyloarthropathyweek trial
Description preview
(1) NIAID 15-I-N070: Radiologic and immunologic biomarkers to enhance early bactericidal activity (EBA) measurements of sterilizing drug activity in tuberculosis (NexGen EBA). This study hypothesized that drug regimens associated with higher sterilizing activity show distinct cytokine patterns and quantifiable PET/CT changes in certain lesions…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click